The β2‐Glycoprotein I/HLA–DR Complex As a Major Autoantibody Target in Obstetric Antiphospholipid Syndrome

ObjectiveThe clinical manifestations of antiphospholipid syndrome (APS) include vascular thrombosis and pregnancy morbidity as well as recurrent pregnancy loss (RPL). However, in more than half of patients with RPL, the cause is never determined. Recently, β2‐glycoprotein I (β2GPI) complexed with HL...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2020-11, Vol.72 (11), p.1882-1891
Hauptverfasser: Tanimura, Kenji, Saito, Shigeru, Nakatsuka, Mikiya, Nagamatsu, Takeshi, Fujii, Tomoyuki, Fukui, Atsushi, Deguchi, Masashi, Sasagawa, Yuki, Arase, Noriko, Arase, Hisashi, Yamada, Hideto
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1891
container_issue 11
container_start_page 1882
container_title Arthritis & rheumatology (Hoboken, N.J.)
container_volume 72
creator Tanimura, Kenji
Saito, Shigeru
Nakatsuka, Mikiya
Nagamatsu, Takeshi
Fujii, Tomoyuki
Fukui, Atsushi
Deguchi, Masashi
Sasagawa, Yuki
Arase, Noriko
Arase, Hisashi
Yamada, Hideto
description ObjectiveThe clinical manifestations of antiphospholipid syndrome (APS) include vascular thrombosis and pregnancy morbidity as well as recurrent pregnancy loss (RPL). However, in more than half of patients with RPL, the cause is never determined. Recently, β2‐glycoprotein I (β2GPI) complexed with HLA class II molecules (β2GPI/HLA‐DR) was found to be a major autoantibody target in APS. The present study was undertaken to assess the serum levels of autoantibodies against the β2GPI/HLA II complex as a potential risk factor for RPL in women.MethodsSerum levels of antiphospholipid antibodies (aPLs), including IgG/IgM anticardiolipin antibodies, IgG/IgM anti–β2GPI antibodies, and lupus anticoagulant as well as anti‐β2GPI/HLA–DR antibodies, were measured in 227 women with RPL. In this prospective, multicenter, cross‐sectional study, women with RPL and their partners underwent HLA–DR immunotyping and analysis to identify potential causes and risk factors associated with RPL. The normal range for anti‐β2GPI/HLA–DR antibody levels was determined using serum samples obtained from a control population of female subjects (208 women of childbearing potential).ResultsOf the 227 women with RPL, aPL antibodies were detected in 19.8%, and 52 (22.9%) tested positive for anti‐β2GPI/HLA–DR antibodies. Among the 227 women, 121 (53.3%) had no risk factors for RPL, and among these women with unexplained RPL, 24 (19.8%) were positive for anti‐β2GPI/HLA–DR antibodies. Of the 112 women who had clinical symptoms of APS but did not have levels of aPLs that met the diagnostic criteria for APS, 21 (18.8%) were positive for anti‐β2GPI/HLA–DR antibodies.ConclusionThe anti‐β2GPI/HLA–DR antibody is frequently associated with RPL. Detection of these autoantibodies is useful in understanding the pathogenesis of RPL. Our findings may provide potential new therapeutic strategies for addressing RPL in patients with obstetric APS.
doi_str_mv 10.1002/art.41410
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2455575076</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2455575076</sourcerecordid><originalsourceid>FETCH-LOGICAL-j258t-d529b48b38965d231d8696291963abbced5fb5ac1b749b3190145bce48aef0603</originalsourceid><addsrcrecordid>eNo1T11KAzEYDKJgqX3wBgGft-Z_N49L1bZQKWh9LskmtbtsN2uSgn3rEQRv4kE8RE9iQB34mOEbvvkYAK4xGmOEyK3yccwww-gMDAglIuME8fN_jSW-BKMQGpQgcyQQHwC32lr4_UVOx49pe6hc7120dQfnt7NFeTp-3j3Bidv1rX2HZYAKPqrGeVjuo1NdrLUzB7hS_tVGmI6WOkQbfV3BMpn91oU0bd3XBj4fOuPdzl6Bi41qgx398RC8PNyvJrNssZzOJ-UiawgvYmY4kZoVmhZScEMoNoWQgkgsBVVaV9bwjeaqwjpnUlMsEWY8rVmh7CY1o0Nw85ubCr3tbYjrxu19l16uCeOc5xzlgv4AhvldmQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2455575076</pqid></control><display><type>article</type><title>The β2‐Glycoprotein I/HLA–DR Complex As a Major Autoantibody Target in Obstetric Antiphospholipid Syndrome</title><source>Wiley Online Library - AutoHoldings Journals</source><source>Alma/SFX Local Collection</source><creator>Tanimura, Kenji ; Saito, Shigeru ; Nakatsuka, Mikiya ; Nagamatsu, Takeshi ; Fujii, Tomoyuki ; Fukui, Atsushi ; Deguchi, Masashi ; Sasagawa, Yuki ; Arase, Noriko ; Arase, Hisashi ; Yamada, Hideto</creator><creatorcontrib>Tanimura, Kenji ; Saito, Shigeru ; Nakatsuka, Mikiya ; Nagamatsu, Takeshi ; Fujii, Tomoyuki ; Fukui, Atsushi ; Deguchi, Masashi ; Sasagawa, Yuki ; Arase, Noriko ; Arase, Hisashi ; Yamada, Hideto</creatorcontrib><description>ObjectiveThe clinical manifestations of antiphospholipid syndrome (APS) include vascular thrombosis and pregnancy morbidity as well as recurrent pregnancy loss (RPL). However, in more than half of patients with RPL, the cause is never determined. Recently, β2‐glycoprotein I (β2GPI) complexed with HLA class II molecules (β2GPI/HLA‐DR) was found to be a major autoantibody target in APS. The present study was undertaken to assess the serum levels of autoantibodies against the β2GPI/HLA II complex as a potential risk factor for RPL in women.MethodsSerum levels of antiphospholipid antibodies (aPLs), including IgG/IgM anticardiolipin antibodies, IgG/IgM anti–β2GPI antibodies, and lupus anticoagulant as well as anti‐β2GPI/HLA–DR antibodies, were measured in 227 women with RPL. In this prospective, multicenter, cross‐sectional study, women with RPL and their partners underwent HLA–DR immunotyping and analysis to identify potential causes and risk factors associated with RPL. The normal range for anti‐β2GPI/HLA–DR antibody levels was determined using serum samples obtained from a control population of female subjects (208 women of childbearing potential).ResultsOf the 227 women with RPL, aPL antibodies were detected in 19.8%, and 52 (22.9%) tested positive for anti‐β2GPI/HLA–DR antibodies. Among the 227 women, 121 (53.3%) had no risk factors for RPL, and among these women with unexplained RPL, 24 (19.8%) were positive for anti‐β2GPI/HLA–DR antibodies. Of the 112 women who had clinical symptoms of APS but did not have levels of aPLs that met the diagnostic criteria for APS, 21 (18.8%) were positive for anti‐β2GPI/HLA–DR antibodies.ConclusionThe anti‐β2GPI/HLA–DR antibody is frequently associated with RPL. Detection of these autoantibodies is useful in understanding the pathogenesis of RPL. Our findings may provide potential new therapeutic strategies for addressing RPL in patients with obstetric APS.</description><identifier>ISSN: 2326-5191</identifier><identifier>EISSN: 2326-5205</identifier><identifier>DOI: 10.1002/art.41410</identifier><language>eng</language><publisher>Atlanta: Wiley Subscription Services, Inc</publisher><subject>Antibodies ; Anticoagulants ; Antiphospholipid antibodies ; Antiphospholipid syndrome ; Autoantibodies ; Autoimmune diseases ; Cardiolipin ; Diagnostic systems ; Glycoprotein I ; Glycoproteins ; Histocompatibility antigen HLA ; Immunoglobulin G ; Immunoglobulin M ; Morbidity ; Obstetrics ; Pathogenesis ; Pregnancy ; Risk analysis ; Risk factors ; Serum levels ; Thromboembolism ; Thrombosis</subject><ispartof>Arthritis &amp; rheumatology (Hoboken, N.J.), 2020-11, Vol.72 (11), p.1882-1891</ispartof><rights>2020 American College of Rheumatology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Tanimura, Kenji</creatorcontrib><creatorcontrib>Saito, Shigeru</creatorcontrib><creatorcontrib>Nakatsuka, Mikiya</creatorcontrib><creatorcontrib>Nagamatsu, Takeshi</creatorcontrib><creatorcontrib>Fujii, Tomoyuki</creatorcontrib><creatorcontrib>Fukui, Atsushi</creatorcontrib><creatorcontrib>Deguchi, Masashi</creatorcontrib><creatorcontrib>Sasagawa, Yuki</creatorcontrib><creatorcontrib>Arase, Noriko</creatorcontrib><creatorcontrib>Arase, Hisashi</creatorcontrib><creatorcontrib>Yamada, Hideto</creatorcontrib><title>The β2‐Glycoprotein I/HLA–DR Complex As a Major Autoantibody Target in Obstetric Antiphospholipid Syndrome</title><title>Arthritis &amp; rheumatology (Hoboken, N.J.)</title><description>ObjectiveThe clinical manifestations of antiphospholipid syndrome (APS) include vascular thrombosis and pregnancy morbidity as well as recurrent pregnancy loss (RPL). However, in more than half of patients with RPL, the cause is never determined. Recently, β2‐glycoprotein I (β2GPI) complexed with HLA class II molecules (β2GPI/HLA‐DR) was found to be a major autoantibody target in APS. The present study was undertaken to assess the serum levels of autoantibodies against the β2GPI/HLA II complex as a potential risk factor for RPL in women.MethodsSerum levels of antiphospholipid antibodies (aPLs), including IgG/IgM anticardiolipin antibodies, IgG/IgM anti–β2GPI antibodies, and lupus anticoagulant as well as anti‐β2GPI/HLA–DR antibodies, were measured in 227 women with RPL. In this prospective, multicenter, cross‐sectional study, women with RPL and their partners underwent HLA–DR immunotyping and analysis to identify potential causes and risk factors associated with RPL. The normal range for anti‐β2GPI/HLA–DR antibody levels was determined using serum samples obtained from a control population of female subjects (208 women of childbearing potential).ResultsOf the 227 women with RPL, aPL antibodies were detected in 19.8%, and 52 (22.9%) tested positive for anti‐β2GPI/HLA–DR antibodies. Among the 227 women, 121 (53.3%) had no risk factors for RPL, and among these women with unexplained RPL, 24 (19.8%) were positive for anti‐β2GPI/HLA–DR antibodies. Of the 112 women who had clinical symptoms of APS but did not have levels of aPLs that met the diagnostic criteria for APS, 21 (18.8%) were positive for anti‐β2GPI/HLA–DR antibodies.ConclusionThe anti‐β2GPI/HLA–DR antibody is frequently associated with RPL. Detection of these autoantibodies is useful in understanding the pathogenesis of RPL. Our findings may provide potential new therapeutic strategies for addressing RPL in patients with obstetric APS.</description><subject>Antibodies</subject><subject>Anticoagulants</subject><subject>Antiphospholipid antibodies</subject><subject>Antiphospholipid syndrome</subject><subject>Autoantibodies</subject><subject>Autoimmune diseases</subject><subject>Cardiolipin</subject><subject>Diagnostic systems</subject><subject>Glycoprotein I</subject><subject>Glycoproteins</subject><subject>Histocompatibility antigen HLA</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulin M</subject><subject>Morbidity</subject><subject>Obstetrics</subject><subject>Pathogenesis</subject><subject>Pregnancy</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Serum levels</subject><subject>Thromboembolism</subject><subject>Thrombosis</subject><issn>2326-5191</issn><issn>2326-5205</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNo1T11KAzEYDKJgqX3wBgGft-Z_N49L1bZQKWh9LskmtbtsN2uSgn3rEQRv4kE8RE9iQB34mOEbvvkYAK4xGmOEyK3yccwww-gMDAglIuME8fN_jSW-BKMQGpQgcyQQHwC32lr4_UVOx49pe6hc7120dQfnt7NFeTp-3j3Bidv1rX2HZYAKPqrGeVjuo1NdrLUzB7hS_tVGmI6WOkQbfV3BMpn91oU0bd3XBj4fOuPdzl6Bi41qgx398RC8PNyvJrNssZzOJ-UiawgvYmY4kZoVmhZScEMoNoWQgkgsBVVaV9bwjeaqwjpnUlMsEWY8rVmh7CY1o0Nw85ubCr3tbYjrxu19l16uCeOc5xzlgv4AhvldmQ</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Tanimura, Kenji</creator><creator>Saito, Shigeru</creator><creator>Nakatsuka, Mikiya</creator><creator>Nagamatsu, Takeshi</creator><creator>Fujii, Tomoyuki</creator><creator>Fukui, Atsushi</creator><creator>Deguchi, Masashi</creator><creator>Sasagawa, Yuki</creator><creator>Arase, Noriko</creator><creator>Arase, Hisashi</creator><creator>Yamada, Hideto</creator><general>Wiley Subscription Services, Inc</general><scope>7QL</scope><scope>7QP</scope><scope>7T5</scope><scope>7TM</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope></search><sort><creationdate>20201101</creationdate><title>The β2‐Glycoprotein I/HLA–DR Complex As a Major Autoantibody Target in Obstetric Antiphospholipid Syndrome</title><author>Tanimura, Kenji ; Saito, Shigeru ; Nakatsuka, Mikiya ; Nagamatsu, Takeshi ; Fujii, Tomoyuki ; Fukui, Atsushi ; Deguchi, Masashi ; Sasagawa, Yuki ; Arase, Noriko ; Arase, Hisashi ; Yamada, Hideto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j258t-d529b48b38965d231d8696291963abbced5fb5ac1b749b3190145bce48aef0603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antibodies</topic><topic>Anticoagulants</topic><topic>Antiphospholipid antibodies</topic><topic>Antiphospholipid syndrome</topic><topic>Autoantibodies</topic><topic>Autoimmune diseases</topic><topic>Cardiolipin</topic><topic>Diagnostic systems</topic><topic>Glycoprotein I</topic><topic>Glycoproteins</topic><topic>Histocompatibility antigen HLA</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulin M</topic><topic>Morbidity</topic><topic>Obstetrics</topic><topic>Pathogenesis</topic><topic>Pregnancy</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Serum levels</topic><topic>Thromboembolism</topic><topic>Thrombosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tanimura, Kenji</creatorcontrib><creatorcontrib>Saito, Shigeru</creatorcontrib><creatorcontrib>Nakatsuka, Mikiya</creatorcontrib><creatorcontrib>Nagamatsu, Takeshi</creatorcontrib><creatorcontrib>Fujii, Tomoyuki</creatorcontrib><creatorcontrib>Fukui, Atsushi</creatorcontrib><creatorcontrib>Deguchi, Masashi</creatorcontrib><creatorcontrib>Sasagawa, Yuki</creatorcontrib><creatorcontrib>Arase, Noriko</creatorcontrib><creatorcontrib>Arase, Hisashi</creatorcontrib><creatorcontrib>Yamada, Hideto</creatorcontrib><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><jtitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tanimura, Kenji</au><au>Saito, Shigeru</au><au>Nakatsuka, Mikiya</au><au>Nagamatsu, Takeshi</au><au>Fujii, Tomoyuki</au><au>Fukui, Atsushi</au><au>Deguchi, Masashi</au><au>Sasagawa, Yuki</au><au>Arase, Noriko</au><au>Arase, Hisashi</au><au>Yamada, Hideto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The β2‐Glycoprotein I/HLA–DR Complex As a Major Autoantibody Target in Obstetric Antiphospholipid Syndrome</atitle><jtitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</jtitle><date>2020-11-01</date><risdate>2020</risdate><volume>72</volume><issue>11</issue><spage>1882</spage><epage>1891</epage><pages>1882-1891</pages><issn>2326-5191</issn><eissn>2326-5205</eissn><abstract>ObjectiveThe clinical manifestations of antiphospholipid syndrome (APS) include vascular thrombosis and pregnancy morbidity as well as recurrent pregnancy loss (RPL). However, in more than half of patients with RPL, the cause is never determined. Recently, β2‐glycoprotein I (β2GPI) complexed with HLA class II molecules (β2GPI/HLA‐DR) was found to be a major autoantibody target in APS. The present study was undertaken to assess the serum levels of autoantibodies against the β2GPI/HLA II complex as a potential risk factor for RPL in women.MethodsSerum levels of antiphospholipid antibodies (aPLs), including IgG/IgM anticardiolipin antibodies, IgG/IgM anti–β2GPI antibodies, and lupus anticoagulant as well as anti‐β2GPI/HLA–DR antibodies, were measured in 227 women with RPL. In this prospective, multicenter, cross‐sectional study, women with RPL and their partners underwent HLA–DR immunotyping and analysis to identify potential causes and risk factors associated with RPL. The normal range for anti‐β2GPI/HLA–DR antibody levels was determined using serum samples obtained from a control population of female subjects (208 women of childbearing potential).ResultsOf the 227 women with RPL, aPL antibodies were detected in 19.8%, and 52 (22.9%) tested positive for anti‐β2GPI/HLA–DR antibodies. Among the 227 women, 121 (53.3%) had no risk factors for RPL, and among these women with unexplained RPL, 24 (19.8%) were positive for anti‐β2GPI/HLA–DR antibodies. Of the 112 women who had clinical symptoms of APS but did not have levels of aPLs that met the diagnostic criteria for APS, 21 (18.8%) were positive for anti‐β2GPI/HLA–DR antibodies.ConclusionThe anti‐β2GPI/HLA–DR antibody is frequently associated with RPL. Detection of these autoantibodies is useful in understanding the pathogenesis of RPL. Our findings may provide potential new therapeutic strategies for addressing RPL in patients with obstetric APS.</abstract><cop>Atlanta</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1002/art.41410</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2326-5191
ispartof Arthritis & rheumatology (Hoboken, N.J.), 2020-11, Vol.72 (11), p.1882-1891
issn 2326-5191
2326-5205
language eng
recordid cdi_proquest_journals_2455575076
source Wiley Online Library - AutoHoldings Journals; Alma/SFX Local Collection
subjects Antibodies
Anticoagulants
Antiphospholipid antibodies
Antiphospholipid syndrome
Autoantibodies
Autoimmune diseases
Cardiolipin
Diagnostic systems
Glycoprotein I
Glycoproteins
Histocompatibility antigen HLA
Immunoglobulin G
Immunoglobulin M
Morbidity
Obstetrics
Pathogenesis
Pregnancy
Risk analysis
Risk factors
Serum levels
Thromboembolism
Thrombosis
title The β2‐Glycoprotein I/HLA–DR Complex As a Major Autoantibody Target in Obstetric Antiphospholipid Syndrome
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T14%3A39%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20%CE%B22%E2%80%90Glycoprotein%20I/HLA%E2%80%93DR%20Complex%20As%20a%20Major%20Autoantibody%20Target%20in%20Obstetric%20Antiphospholipid%20Syndrome&rft.jtitle=Arthritis%20&%20rheumatology%20(Hoboken,%20N.J.)&rft.au=Tanimura,%20Kenji&rft.date=2020-11-01&rft.volume=72&rft.issue=11&rft.spage=1882&rft.epage=1891&rft.pages=1882-1891&rft.issn=2326-5191&rft.eissn=2326-5205&rft_id=info:doi/10.1002/art.41410&rft_dat=%3Cproquest%3E2455575076%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2455575076&rft_id=info:pmid/&rfr_iscdi=true